电子烟或雾化产品使用相关肺损伤患者呼吸衰竭的体外生命支持
该研究为多机构国际回顾性病例系列,纳入10家机构、3个国家共14例符合确诊标准的电子烟或雾化产品使用相关肺损伤并接受体外生命支持的患者,年龄16至45岁。所有患者均为就诊前3个月内确认使用雾化产品,均有呼吸道症状和双肺浸润影,普遍接受静脉抗生素和糖皮质激素治疗。体外生命支持前插管时间中位1.9天(范围0至6天),主要指征为氧合和通气不佳;作者结论认为静脉-静脉体外生命支持可能是该类患者难治性呼吸衰竭的有效治疗选择。
要点
- 体外生命支持前插管时间中位1.9天(范围0至6天),主要上机指征为氧合和通气不佳。
- 所有患者均有呼吸道症状和双肺浸润影,均接受静脉抗生素和糖皮质激素治疗。
- 该研究为回顾性病例系列,样本仅14例,不能据此确立体外生命支持的常规推荐。
适用人群与场景
- 符合既往报告确诊标准的电子烟或雾化产品使用相关肺损伤患者,且已接受体外生命支持;来自10家机构、3个国家的16至45岁患者。
- 所有患者均有就诊前3个月内确认的雾化产品使用史,尼古丁为最常用产品。
诊断标准与关键阈值
- 电子烟或雾化产品使用相关肺损伤确诊基于既往报告的诊断标准(原文未列出具体条件与界值)。
- 体外生命支持指征为氧合和通气不佳(原文未给出具体氧合或通气阈值)。
处置流程与药物剂量
- 第一步:所有患者均启动静脉抗生素和糖皮质激素治疗(原文未给出具体药名、剂量、途径和疗程)。
- 第二步:因氧合和通气不佳行气管插管,插管后中位1.9天(范围0至6天)启动体外生命支持。
红旗征与不能漏的情况
- 难治性呼吸衰竭和低氧血症:原文结论指出电子烟相关肺损伤可导致难治性呼吸衰竭和低氧血症,需考虑体外生命支持。
- 心室功能障碍:5例超声心动图显示心室功能障碍(原文未给出具体处理)。
- 感染性休克:1例死亡原因为感染性休克。
研究设计与关键结果
- 研究类型为多机构国际回顾性病例系列,共14例患者,来自10家机构、3个国家,年龄16至45岁。
- 所有患者均有呼吸道症状和双肺浸润影,均接受静脉抗生素和糖皮质激素;尼古丁为最常用雾化产品。
证据类型、等级与局限
- 证据类型为回顾性病例系列(多机构、国际),非对照研究。
- 局限:样本量小(14例)、回顾性设计、无对照组,原文未提及前瞻性验证。
对床旁实践的改变
- 对于电子烟或雾化产品使用相关肺损伤导致难治性呼吸衰竭和低氧血症的患者,静脉-静脉体外生命支持可作为治疗选择之一。
- 该证据来自14例回顾性病例系列,不能据此扩大体外生命支持适应证或改变常规上机阈值。
- 原文未提及适用与不适用人群的具体排除标准,临床决策需个体化。
指南或共识出处
- 原文未提及指南或共识名称;文献发表于Crit Care Med。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Electronic cigarette or vaping product use-associated lung injury is a clinical entity that can lead to respiratory failure and death. Despite the severity of electronic cigarette or vaping product use-associated lung injury, the role of extracorporeal life support in its management remains unclear. Our objective was to describe the clinical characteristics and outcomes of patients with electronic cigarette or vaping product use-associated lung injury who received extracorporeal life support.
DESIGN: We performed a retrospective review of records of electronic cigarette or vaping product use-associated lung injury patients who received extracorporeal life support. Standardized data were collected via direct contact with extracorporeal life support centers. Data regarding presentation, ventilatory management, extracorporeal life support details, and outcome were analyzed.
SETTING: This was a multi-institutional, international case series with patients from 10 different institutions in three different countries.
PATIENTS: Patients who met criteria for confirmed electronic cigarette or vaping product use-associated lung injury (based on previously reported diagnostic criteria) and were placed on extracorporeal life support were included. Patients were identified via literature review and by direct contact with extracorporeal life support centers.
MEASUREMENTS AND MAIN RESULTS: Data were collected for 14 patients ranging from 16 to 45 years old. All had confirmed vape use within 3 months of presentation. Nicotine was the most commonly used vaping product. All patients had respiratory symptoms and radiographic evidence of bilateral pulmonary opacities. IV antibiotics and corticosteroids were universally initiated. Patients were intubated for 1.9 days (range, 0-6) prior to extracorporeal life support initiation. Poor oxygenation and ventilation were the most common indications for extracorporeal life support. Five patients showed evidence of ventricular dysfunction on echocardiography. Thirteen patients (93%) were placed on venovenous extracorporeal life support, and one patient required multiple rounds of extracorporeal life support. Total extracorporeal life support duration ranged from 2 to 37 days. Thirteen patients survived to hospital discharge; one patient died of septic shock.
CONCLUSIONS: Electronic cigarette or vaping product use-associated lung injury can cause refractory respiratory failure and hypoxemia. These data suggest that venovenous extracorporeal life support can be an effective treatment option for profound, refractory respiratory failure secondary to electronic cigarette or vaping product use-associated lung injury.
参考来源
- Gupta VS, Hayes D, Hsu SC, et al. Extracorporeal Life Support for Respiratory Failure in Patients With Electronic Cigarette or Vaping Product Use-Associated Lung Injury. Crit Care Med. 2022. PMID: 34524154. doi:10.1097/CCM.0000000000005299
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。